MBOT

Business Context and Reporting Period

Company: StemCells, Inc. (formerly CytoTherapeutics, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2000
Business Overview: The Company has restructured to focus exclusively on its proprietary stem cell technology platform. It has wound down operations related to its former encapsulated cell technology (ECT), terminated a clinical trial, and relocated headquarters from Rhode Island to Sunnyvale, California. The Company has no commercial product sales and relies on external financing and collaborative arrangements.

Key Financial Metrics

Note: The significant increase in Total Assets is primarily due to the fair value adjustment of the Modex Therapeutics investment.

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped to $0 from $5.02 million in the prior year due to the termination of a collaborative agreement related to the former ECT program in June 1999. No new revenue-producing collaborations for stem cell technology have been established.
• Expense Reduction: Research and Development (R&D) expenses decreased by 76% to $1.66 million, and General and Administrative (G&A) expenses decreased by 4% to $2.08 million. These reductions are attributed to the wind-down of ECT operations and the establishment of a smaller corporate office.
• Investment Gain: The Company recorded a non-operating gain of approximately $1.42 million related to its investment in Modex Therapeutics Ltd. following Modex's IPO. This gain significantly offset the operating loss.
• Liquidity Improvement: Net cash used in operating activities improved significantly to ($0.92 million) from ($4.50 million) in the prior period. Cash balances increased by $0.78 million during the six-month period.

Outlook, Risks, and Management Commentary

• Capital Resources: Management expects existing capital resources to fund operations into the first quarter of 2001. The Company requires substantial additional funding for R&D, clinical trials, and facility costs.
• Recent Financing: On August 3, 2000 (subsequent to period end), the Company completed a $4 million common stock financing with Millennium Partners, LP. $3 million was received at closing, with $1 million pending registration effectiveness.
• Facility Obligations: The Company faces significant ongoing costs (~$1.95 million annually) for facilities in Rhode Island related to the former ECT program. Failure to sublease, assign, or sell these interests could materially adversely affect liquidity.
• Risks: Key risks include the inability to secure corporate partners for stem cell programs, delays in clinical testing, obsolescence of technology, and the volatility of the Modex Therapeutics investment value.
• Guidance: The Company does not expect to generate revenue from product sales for at least several years and anticipates continuing operating losses.

Investor Verification Checklist

• Modex Investment Valuation: Verify the current fair value and liquidity status of the $19.2 million Modex Therapeutics holding, noting the 6-month lock-up period post-IPO.
• Facility Exit Strategy: Confirm progress on subleasing or selling the Rhode Island facilities to mitigate the ~$1.95 million annual cost burden.
• Financing Terms: Review the specific terms of the Millennium Partners financing, including the mechanism for additional share entitlements and the warrant exercise price.
• Runway: Assess whether the $5.5 million cash balance plus the $3 million financing proceeds is sufficient to reach the next milestone given the lack of operating revenue.
• Preferred Stock Conversion: Monitor the status of the $1.5 million convertible preferred stock issued to Board members and any potential dilution from the "make-whole" provisions if future offerings do not meet thresholds.